Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Trial
OBJECTIVES:
I. Compare and evaluate the response to treatment with intravenous human immune globulin
(IVIG) or placebo in previously untreated patients with chronic inflammatory demyelinating
polyneuropathy.
PROTOCOL OUTLINE: This is a double blind, randomized, controlled study. Patients receive
either intravenous human immune globulin (IVIG) or placebo infused at a rate of 40 mL/hr,
increasing every 30 min to a maximum of 100 mL/hr daily over 6 to 8 hours for 2 days. On day
2, infusions of IVIG or placebo are delivered at the highest dose tolerated on day 1.
On day 21, patients receive another IVIG or placebo infusion. Following day 42, patients may
choose to continue infusions of IVIG every 21 days for 2 doses.
Patients not receiving additional treatment are released from study. Patients are evaluated
on days 10, 21, and 43.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05327114 -
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02271724 -
sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN
|
N/A | |
| Completed |
NCT00004772 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy
|
Phase 3 | |
| Completed |
NCT03008733 -
Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuropathy With Antibody A MAG
|
N/A | |
| Active, not recruiting |
NCT05877040 -
A Proof of Concept Study With Rituximab in Patients With CIDP Not Responding to Conventional Immune Therapy
|
Phase 2 | |
| Completed |
NCT02027701 -
Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
| Terminated |
NCT03275740 -
A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347
|
Phase 1 | |
| Completed |
NCT04742374 -
Effects of Single Plasma Exchange and Double Filtration Plasmapheresis (DFPP) on Peripheral Lymphocyte Phenotypes in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
Early Phase 1 | |
| Completed |
NCT00305266 -
Study of CIDP Patients During IVIG Treatment
|
N/A | |
| Completed |
NCT00004939 -
Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy
|
Phase 3 | |
| Completed |
NCT01017159 -
Subcutaneous Immunoglobulin Treatment of Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|
Phase 2 | |
| Completed |
NCT00220740 -
Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|
Phase 3 | |
| Completed |
NCT06325943 -
Rituximab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy
|
Phase 3 |